12Evidence A

Prefer generic drugs that have passed consistency evaluation and those selected in centralized procurement

The second batch of centrally procured drugs saw an average price drop of 53%, with some drugs becoming 93% cheaper. As of April 2026, 11 procurement rounds have been completed, covering 490 different drugs. Asking for generic drugs from this program ensures you get the same ingredients at a much lower price.

Cost

No cost at all. When a doctor prescribes medication or you…

Benefit

The national centralized drug procurement initiative resulted in a 53% average price reduction for the second…

Cost

No cost at all. When a doctor prescribes medication or you go to buy medicine, simply ask: “Is there a generic version included in the centralized procurement program?”

Benefit

The national centralized drug procurement initiative resulted in a 53% average price reduction for the second batch, with some drugs dropping by as much as 93%. By April 2026, 11 rounds had been conducted, covering 490 drugs. A total of 1,695 drugs have either passed or are considered to have met consistency evaluation standards, accounting for roughly two-thirds of all commonly used chemical drugs in China (official data from 2020–2026).

Original sources

国家医疗保障局 (2020). 第二批国家组织药品集中采购和使用工作答记者问. https://www.nhsa.gov.cn/art/2020/1/17/art_38_2264.html;国家医疗保障局 (2026). 国务院政策例行吹风会:健全全周期全渠道药品价格形成机制. http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html;国务院办公厅 (2016). 关于开展仿制药质量和疗效一致性评价的意见(国办发〔2016〕8 号). https://www.gov.cn/zhengce/zhengceku/2016-03/05/content_5049364.htm;国家食品药品监督管理总局 (2016). 关于发布普通口服固体制剂参比制剂选择和确定等 3 个技术指导原则的通告(2016 年第 61 号)附件 1、附件 3,海南省药品监督管理局转载. https://amr.hainan.gov.cn/himpa/ztzl/fzy/201607/t20160720_1591587.html;国家医疗保障局 (2024). 集采药品质量严格监管,企业检查和品种抽检两个「全覆盖」. https://www.nhsa.gov.cn/art/2024/12/30/art_52_15287.html;国家医疗保障局 (2025). 医保部门、药监部门有关同志就集采药品相关问题接受人民日报健康客户端记者采访. https://www.nhsa.gov.cn/art/2025/2/9/art_14_15647.html

Open source link
Book note

Controversy: People often say that "consistency evaluation only compares ingredients, not efficacy." This statement is only half true. The practice of consistency evaluation involves having healthy individuals take the medication and then performing blood tests to observe the concentration curve of the drug after it enters the bloodstream. This curve is then compared with that of the original brand-name drug; if it falls between 80% and 125%, it is considered to have passed. For types of drugs where even a slight dosage difference can cause issues, the requirements are even stricter. Excipients refer to the fillers and coatings other than the active ingredients, and they are permitted to be different from the original brand-name drug. Regulations only require that the active ingredients, dosage form, administration method, and therapeutic effect be the same. Therefore, it is indeed not a matter of "finding patients to take the drug for a period of time to see if they recover." The effects on patients are answered by another set of studies. The National Healthcare Security Administration organized hospitals to conduct real-world studies. As of December 2024, these covered 63 types of centralized procurement drugs, nearly one hundred tertiary hospitals, and over 300,000 patients. The results showed no difference compared to the original brand-name drugs. For example, with Metformin, the HbA1c target achievement rate was 83.4% for the generic group and 78.9% for the original group. Conversely, for fasting blood glucose target achievement rates, the generic group was 83.8% and the original group was 87.6%. The two groups fluctuated relative to each other. In January 2025, some doctors publicly stated that centralized procurement drugs cause "blood pressure not to drop, anesthesia not to induce sleep, and laxatives not to induce bowel movements." The Healthcare Security Administration and the drug regulatory authorities went to 7 hospitals in Shanghai to investigate, and the conclusion was that these claims mostly originated from hearsay and personal feelings. The specific laxative that was named had not yet begun to be used in hospitals at that time. During the same period, it was also admitted that problematic drugs had indeed been sampled. Among the more than 1,600 selected products in the first 9 batches, 9 were disqualified due to quality risks. Among these 9, 6 were imported drugs (including 3 original brand-name drugs) and 3 were domestic drugs. There are two things you can implement. First, if you wish to continue using the original brand-name drug, it can usually still be prescribed. Centralized procurement only accounts for 60% to 80% of hospital procurement volume; the remainder is determined by the hospitals themselves. Original brand-name drugs are not banned, but the cost is paying more out of your own pocket. Second, after switching medications for chronic diseases, do not judge based on feeling; keep track of blood pressure, blood glucose, and HbA1c according to Section 16, Item 3 (record every metric in the same notebook). If things truly worsen, go see a doctor and ask the doctor to report adverse drug reactions; do not stop the medication yourself.

My note